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Abdominal Aortic Bifurcation Anatomy and Endograft
Limbs Size Affect the Use of Adjunctive Iliac Stenting
during Endovascular Abdominal Aortic Aneurysm Re-
pair
Claudio Bianchini Massoni1, Mauro Gargiulo1, Antonio
Freyrie1, Enrico Gallitto1, Federica Giovanetti1, Joseph J.
Ricotta2, Andrea Stella1. 1Vascular Surgery, University of
Bologna, Bologna, Italy; 2Vascular Surgery, Emory Uni-
versity, Atlanta, GA
Objectives: Post-angioplasty residual stenosis 50%
(PRS) of iliac endograft limb after endovascular abdom-
inal aneurysm repair (EVAR) is an indication for intra-
operative adjunctive stenting. The aim of the study is to
determinate if abdominal aortic bifurcation diameter
(AB), ratio of sum of iliac limb diameters to aortic
bifurcation diameter (IL/AB) and aortic bifurcation cal-
cification influence the PRS.
Methods: Post-angioplasty residual stenosis 50%
(PRS) of iliac endograft limb after endovascular abdom-
inal aneurysm repair (EVAR) is an indication for intra-
operative adjunctive stenting. The aim of the study is to
determinate if abdominal aortic bifurcation diameter
(AB), ratio of sum of iliac limb diameters to aortic
bifurcation diameter (IL/AB) and aortic bifurcation cal-
cification influence the PRS.
Results: Two hundred forty-seven patients (233
men; mean age 74  7 years) with 494 endograft limbs
were evaluated. Mean AB was 28.9 mm  12.9 mm.
Median endograft iliac leg diameter was 16 mm. AB was
 20 mm in 70 patients(28%), IL/AB was 1.4 in 35%,
AB 20 mm associated with IL/AB 1.4 in 22% and
aortic bifurcation calcification 25% in 61% of patients.
Thirty-six (15%) aortic bifurcations developed PRS and
were treated with adjunctive stenting. In this group, AB
was 20 mm in 42%, IL/AB1.4 in 56%, AB 20 mm
associated with IL/AB 1.4 in 36% and aortic bifurca-
tion calcification 25% in 67% of patients. The mean
follow up was 36 months (range 6-65 months).Multi-
variate analysis identified AB 20 mm, IL/AB 1.4 and
IL/AB 1.4 associated with calcification  25% as
predictive factors for PRS (P.05, P.007 and P.015
respectively). Technical success and mid-term (36
months) clinical success were 100%.
Conclusions: PRS of iliac endograft is a common
pattern in the EVAR. AB 20 mm, ILs/AB 1.4 and
aortic bifurcation calcification 25% associated with
ILs/AB1.4 are statistically correlated with PRS. Adjunc-
tive stenting is a safe procedure and ensures patency in
patients with PRS.
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Increased Rate of Myocardial Infarction with Car-
otid Endarterectomy Under General Anesthesia: A
Population-Based Study
Jaime Benarroch-Gampel, Kristin M. Sheffield, Lorraine
Choi, Casey A. Boyd, Taylor S. Riall, Lois A. Killewich.
Surgery, University of Texas Medical Branch, Galveston,
TX
Objectives: To determine if the incidence of stroke,
myocardial infarction (MI) or death differs in patients
undergoing carotid endarterectomy (CEA) under gen-
eral (GA) versus locoregional (LRA) anesthesia.
Methods: 33,291 patients who underwent CEA
were identified from the National Surgical Quality Im-
provement Program (NSQIP, 2005-2010). The associ-
ation between type of anesthesia (GA vs LRA) and
incidence of perioperative stroke, MI and death was
evaluated.
Results: 27,844 (83.63%) patients received GA, and
were more likely than those who received LRA to have
symptomatic carotid disease (43.9 vs 40.5%, P .0001).
No difference in baseline cardiovascular comorbidities
was seen between groups (42.2 vs 41.2%, P  .63). In
the overall cohort, 1.51% patients had a stroke, 0.66%
had an MI, and 0.60% died within 30 days of surgery.
In both the overall cohort and subgroup analyses, the
perioperative MI rate was higher in patients who under-
went GA compared to LRA (Table). In multivariate
models adjusted for patient demographic and clinical
characteristics, GA patients were 2.2 times more likely to
have an MI compared to those receiving LRA (OR 
2.20, 95% CI  1.36-3.58). No differences between
groups were found in the incidence of perioperative
stroke or death.
Conclusions: The CREST trial found a decreased rate
of perioperative stroke in patients undergoing CEA com-
pared to carotid stenting, but CEA patients had a higher
rate of MI. Our finding of a reduced rate of MI in patients
undergoing CEA with LRA compared to GA suggests that
CEA using LRA may be the safest procedure for patients
with carotid artery disease.
Table. Unadjusted myocardial infarction rates.
Subgroups
General
(N  27,844)
Locoregional
(N  5447) P value
Overall cohort 0.73% 0.33% .001
Symptomatic carotid
disease
0.83% 0.32% .01
Asymptomatic
carotid disease
0.65% 0.34% .03
With cardiovascular
comorbiditiesa
0.93% 0.44% .01
No cardiovascular
comorbidities
0.58% 0.25% .02
aCHF, MI w/in 6m, angina w/in 1m, PCI, cardiac surgery or PVD
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Asymptomatic 50-75% Internal Carotid Artery Steno-
sis in 288 patients: Risk Factors for Disease Progres-
sion and Ipsilateral Neurological Symptoms
Anahita Dua, Bhavin Patel, Patrick Pindiur, Gary Seabrook,
Peter Rossi. Medical College of Wisconsin, Milwaukee, WI
Objectives: This study identified characteristics of pa-
tients with moderate internal carotid artery stenosis that are
at increased risk for disease progression.
Methods: Patients with asymptomatic moderate inter-
nal carotid disease (peak systolic velocity [PSV] 125cm/
sec and end diastolic velocity [EDV] 125cm/sec by
duplex ultrasonography) correlating to 50-75% diameter
reduction were followed for 3 years. Progression to greater
than 75% diameter reduction (EDV  125cm/sec) or
presentation with focal neurological symptoms (stroke,
amaurosis fugax, transient ischemic attack [TIA]) was doc-
umented. Co-morbidities, smoking status and medications
were recorded. Log-rank testing, Wilcoxson models, and
Kaplan-Meier plots provided statistical analysis.
Results: During 3 year follow up, 26 (9%) of 288
patients (137 men, 151 women) developed symptoms
[stroke: 9 (3.1%), TIA: 3 (1%), amaurosis fugax: 3 (1%)] or
asymptomatic increase in diameter to 75% [11 (3.8%)].
All-cause mortality was 11% (33 patients). 17 patients
(5.9%) underwent carotid endarterectomy and 5 (1.7%)
had carotid stent placement. The event incidence was sig-
nificantly higher for men (P.02), but survival was not
different. The rate of disease progression and/or develop-
ment of symptoms was 5.5% at 12 months and increased to
7.2% by 24 months. Co-morbidities with the highest asso-
ciated event incidences were coronary artery disease [CAD]
(8.1%), hyperlipidemia (7.3%), and hypertension [HTN]
(6.7%). Medications associated with lower event incidences
were insulin (2.8%) and angiotensin receptor blockers
(1.9%).
Conclusions: 9% of patients with asymptomatic mod-
erate carotid stenosis progressed to severe stenosis or de-
veloped ipsilateral neurological symptoms at three year
follow-up. The rate of asymptomatic disease progression or
symptom development was to 7.2% by 24 months. Male
patients with CAD, hyperlipidemia, and HTN are at in-
creased risk and are candidates for frequent screening
and/or early intervention.
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The Value of Near Infrared Spectroscopy and Trans-
cranial Doppler to Predict the Onset of Cerebral
Hyperperfusion Syndrome after Carotid Endarterec-
tomy
Claire W. Pennekamp, Hester den Ruijter, Rogier Immink,
L. Kappelle, Frans L. Moll, Wolfgang Buhre, Cyrille Fer-
rier, Gert-Jan de Borst. Vascular Surgery, UMCU,Utrecht,
Netherlands
Objectives: Cerebral hyperperfusion syndrome
(CHS) after carotid endarterectomy (CEA) is a potential
life-threatening complication. Therefore, early identifi-
cation and treatment of patients at risk is essential. CHS
can be predicted by a doubling of post-operative trans-
cranial Doppler (TCD) derived middle cerebral artery
blood velocity (V) as compared to pre-operative values.
However, in 15% of CEA patients an adequate TCD-
signal cannot be obtained due to an insufficient temporal
bone window. Near infrared spectroscopy (NIRS), esti-
mating the frontal lobe oxygenation (rSO2) could be
used as an alternative cerebral monitoring technique. We
assessed the value of NIRS and peri-operative TCD to
predict CHS after CEA.
Methods: In total, 151 consecutive patients under-
going CEA under general anesthesia having a sufficient
TCD window were prospectively included. V and rSO2
measured before induction of anesthesia were compared
to measurements in the first postoperative hour (
V,

rSO2 respectively). Logistic regression analysis was
performed to determine the relationship between 
V
and 
rSO2 and the occurrence of CHS. ROC curve
analysis was used to determine the optimal cut-off values.
Results: Seven patients developed CHS. 
V and

rSO2 differed between CHS and non-CHS patients
(meanSD), i.e. 6329% vs 2445% and 96% vs 19%
respectively (P .05). Increases in 
V and 
rSO2 were
significantly associated with the occurrence of CHS, inde-
pendent of age and gender, OR 1.47 (95% CI 1.04-2.09)
per 30% increase in V and OR 1.77 (1.06-2.96) per 5%
increase in rSO2. ROC curve analysis showed an AUC of
0.843 for 
V and an optimal cut-off value of 62% increase
(PPV 0.31, NPV 0.98). And an AUC of 0.793 for 
rSO2
and an optimal cut-off value of 3% rSO2 increase (PPV
0.10, NPV 0.99).
Conclusions: Both TCD and NIRS seem to be useful
to safely exclude patients from being at risk to develop
CHS. However, due to the limited number of CHS cases
our results need to be validated in a larger study.
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